Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) by 17.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,276 shares of the company’s stock after buying an additional 791 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Reata Pharmaceuticals were worth $200,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Tudor Investment Corp Et Al raised its stake in shares of Reata Pharmaceuticals by 2.6% during the 3rd quarter. Tudor Investment Corp Et Al now owns 11,833 shares of the company’s stock worth $297,000 after buying an additional 302 shares in the last quarter. Victory Capital Management Inc. increased its stake in Reata Pharmaceuticals by 5.9% in the 3rd quarter. Victory Capital Management Inc. now owns 11,690 shares of the company’s stock valued at $294,000 after purchasing an additional 651 shares in the last quarter. UBS Group AG increased its stake in Reata Pharmaceuticals by 42.2% in the 2nd quarter. UBS Group AG now owns 2,558 shares of the company’s stock valued at $78,000 after purchasing an additional 759 shares in the last quarter. Legal & General Group Plc increased its stake in Reata Pharmaceuticals by 3.9% in the 2nd quarter. Legal & General Group Plc now owns 23,142 shares of the company’s stock valued at $703,000 after purchasing an additional 860 shares in the last quarter. Finally, Macquarie Group Ltd. increased its stake in Reata Pharmaceuticals by 51.1% in the 2nd quarter. Macquarie Group Ltd. now owns 2,768 shares of the company’s stock valued at $84,000 after purchasing an additional 936 shares in the last quarter. 76.13% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Reata Pharmaceuticals

In other news, insider Dawn Carter Bir sold 54,954 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $89.56, for a total transaction of $4,921,680.24. Following the sale, the insider now owns 41,925 shares in the company, valued at $3,754,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Andrea Loewen sold 19,036 shares of Reata Pharmaceuticals stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $83.43, for a total value of $1,588,173.48. Following the transaction, the senior vice president now owns 38,757 shares in the company, valued at $3,233,496.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dawn Carter Bir sold 54,954 shares of Reata Pharmaceuticals stock in a transaction on Monday, March 6th. The shares were sold at an average price of $89.56, for a total value of $4,921,680.24. Following the completion of the transaction, the insider now owns 41,925 shares in the company, valued at approximately $3,754,803. The disclosure for this sale can be found here. Insiders have sold 111,468 shares of company stock worth $9,704,843 over the last quarter. 28.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Robert W. Baird raised their price objective on Reata Pharmaceuticals from $40.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, March 1st. SVB Securities raised their price objective on Reata Pharmaceuticals from $35.00 to $75.00 in a research note on Wednesday, March 1st. The Goldman Sachs Group raised their price target on Reata Pharmaceuticals from $115.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, February 24th. Cantor Fitzgerald raised their price target on Reata Pharmaceuticals from $121.00 to $138.00 and gave the stock an “overweight” rating in a research report on Monday, March 27th. Finally, Citigroup raised their price target on Reata Pharmaceuticals from $53.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.00.

Reata Pharmaceuticals Stock Up 2.3 %

RETA stock opened at $104.79 on Friday. Reata Pharmaceuticals, Inc. has a 52-week low of $18.47 and a 52-week high of $105.29. The stock’s fifty day simple moving average is $90.43 and its 200-day simple moving average is $56.71. The stock has a market capitalization of $3.85 billion, a price-to-earnings ratio of -12.24 and a beta of 1.53.

Reata Pharmaceuticals Profile

(Get Rating)

Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.